Abstract
Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. The available data suggest that efforts to reduce mortality in the CKD population should be focused on treatment and prevention of, among others, coronary artery disease and congestive heart failure. Accelerated atherosclerosis present in CKD patients also leads to a decline in renal function. Definite data concerning the treatment of heart failure in CKD patients are lacking, because patients with significant renal impairment have mostly been excluded from randomized studies. Nevertheless, it seems that CKD patients should receive similar cardiovascular treatment to that used in patients with normal kidney function, but the doses of drugs ought to be titrated to achieve an optimal effect while avoiding adverse events. Several studies have also shown that despite the high risk, in patients with acute coronary syndrome (ACS), revascularization procedures in patients with CKD appear to be advantageous in the long run and are therefore justified. However, large clinical trials are needed to confirm the benefits and to identify possible disadvantages associated with various methods of treatment.
Keywords: Acute coronary syndrome, chronic kidney disease, coronary interventions, treatment.
Current Vascular Pharmacology
Title:Acute Coronary Syndromes in Patients with Chronic Kidney Disease
Volume: 11 Issue: 5
Author(s): Beata Franczyk-Skóra, Anna Gluba, Maciej Banach, Piotr Rozentryt, Lech Poloński and Jacek Rysz
Affiliation:
Keywords: Acute coronary syndrome, chronic kidney disease, coronary interventions, treatment.
Abstract: Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. The available data suggest that efforts to reduce mortality in the CKD population should be focused on treatment and prevention of, among others, coronary artery disease and congestive heart failure. Accelerated atherosclerosis present in CKD patients also leads to a decline in renal function. Definite data concerning the treatment of heart failure in CKD patients are lacking, because patients with significant renal impairment have mostly been excluded from randomized studies. Nevertheless, it seems that CKD patients should receive similar cardiovascular treatment to that used in patients with normal kidney function, but the doses of drugs ought to be titrated to achieve an optimal effect while avoiding adverse events. Several studies have also shown that despite the high risk, in patients with acute coronary syndrome (ACS), revascularization procedures in patients with CKD appear to be advantageous in the long run and are therefore justified. However, large clinical trials are needed to confirm the benefits and to identify possible disadvantages associated with various methods of treatment.
Export Options
About this article
Cite this article as:
Franczyk-Skóra Beata, Gluba Anna, Banach Maciej, Rozentryt Piotr, Poloński Lech and Rysz Jacek, Acute Coronary Syndromes in Patients with Chronic Kidney Disease, Current Vascular Pharmacology 2013; 11 (5) . https://dx.doi.org/10.2174/1570161111311050013
DOI https://dx.doi.org/10.2174/1570161111311050013 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Assessment of a Protease Inhibitor Peptide for Anti-Ageing
Protein & Peptide Letters Is the Cytoskeleton an Intracellular Receptor for Adrenomedullin and PAMP?
Current Protein & Peptide Science Relationship Between Na<sup>+</sup>, K<sup>+</sup>-ATPase and NMDA Receptor at Central Synapses
Current Protein & Peptide Science Variability in Response to Cardiovascular Drugs
Current Clinical Pharmacology Diabetes and Atherosclerosis: Old Players in a New Field, Osteoporosis
Current Vascular Pharmacology Prediction of Cardiovascular Risk Using Extreme Learning Machine-Tree Classifier on Apache Spark Cluster
Recent Advances in Computer Science and Communications The Role of the O-GlcNAc Modification in Regulating Eukaryotic Gene Expression
Current Signal Transduction Therapy Effect of Doxycycline on Atherosclerosis: From Bench to Bedside
Recent Patents on Cardiovascular Drug Discovery Cardiovascular Molecular Imaging: New Methodological Strategies
Current Pharmaceutical Design Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design Delirium in Older Patients – A Review
Current Psychiatry Reviews Pathogenetic Pathways of Cardiorenal Syndrome and their Possible Therapeutic Implications
Current Pharmaceutical Design The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Endoplasmic Reticulum Stress in Arterial Smooth Muscle Cells: A Novel Regulator of Vascular Disease
Current Cardiology Reviews Glycaemic Control: A Balancing Act or A Different Approach?
Current Diabetes Reviews Hypoxia Inducible Factor-1 in Cancer Immune Suppression
Current Immunology Reviews (Discontinued) The Therapeutic Potential of Rutin for Diabetes: An Update
Mini-Reviews in Medicinal Chemistry